Pricing For Profit: The Dilemma Of Commercial Science Publishers

Over the past two to three years, commercial publishers have been called a lot of names: greedy, rapacious, price-gouging, and so forth. Usually these remarks are made when comparing commercial journal prices with the prices of journals published by those who have the advantage of the high moral ground: learned societies. Why, it is asked (or, worse, not asked), does an American Chemical Society journal cost perhaps 10 cents per page, while an ier journal costs 25 cents per page? Let me quickly

Written byKaren Hunter
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Over the past two to three years, commercial publishers have been called a lot of names: greedy, rapacious, price-gouging, and so forth. Usually these remarks are made when comparing commercial journal prices with the prices of journals published by those who have the advantage of the high moral ground: learned societies. Why, it is asked (or, worse, not asked), does an American Chemical Society journal cost perhaps 10 cents per page, while an ier journal costs 25 cents per page? Let me quickly review the very great differences between the cost and revenue structures of society and nonsociety publishers.

Societies gain revenues from several sources:

In addition, they have postal subsidies and pay little or no taxes.

[By contrast], commercial publishers generally have revenue from only two sources: library subscriptions and reprints. We generally collect no page charges (not because we do not want to have them, but most researchers ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies